All Outputs (41)

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review (2024)
Journal Article

In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or int... Read More about Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review.

The IUPHAR/BPS Guide to PHARMACOLOGY in 2024 (2023)
Journal Article

The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb; https://www.guidetopharmacology.org) is an open-access, expert-curated, online database that provides succinct overviews and key references for pharmacological targets and their recommended experimental l... Read More about The IUPHAR/BPS Guide to PHARMACOLOGY in 2024.

Advances in malaria pharmacology and the online guide to MALARIA PHARMACOLOGY: IUPHAR review 38 (2023)
Journal Article

Antimalarial drug discovery has until recently been driven by high-throughput phenotypic cellular screening, allowing millions of compounds to be assayed and delivering clinical drug candidates. In this review, we will focus on target-based approache... Read More about Advances in malaria pharmacology and the online guide to MALARIA PHARMACOLOGY: IUPHAR review 38.

Looking Under the Lamppost: The Search for New Cancer Targets in the Human Kinome (2022)
Journal Article

The number of cancer drugs is increasing as new chemical entities are developed to target molecules, often protein kinases, driving cancer progression. In 2009, Fedorov et al. identified that of the protein kinases in the human kinome, most of the fo... Read More about Looking Under the Lamppost: The Search for New Cancer Targets in the Human Kinome.

Development of a novel cell-based, In-Cell Western/ERK assay system for the high-throughput screening of agonists acting on the delta-opioid receptor (2022)
Journal Article

Background: Extracellular signal-regulated kinases (ERKs) are important signaling mediators in mammalian cells and, as a result, one of the major areas of research focus. The detection and quantification of ERK phosphorylation as an index of activati... Read More about Development of a novel cell-based, In-Cell Western/ERK assay system for the high-throughput screening of agonists acting on the delta-opioid receptor.

Environmental pharmacology—Dosing the environment: IUPHAR review 36 (2022)
Journal Article

Pesticide action is predominantly measured as a toxicological outcome, with pharmacological impact of sublethal doses on bystander species left largely undocumented. Likewise, chronic exposure, which often results in responses different from acute ad... Read More about Environmental pharmacology—Dosing the environment: IUPHAR review 36.

Perspective article: A proposal for rational drug class terminology (2022)
Journal Article

Collective names for drugs were coined for various reasons, some of which we would now recognise as misguided.

Planning experiments: Updated guidance on experimental design and analysis and their reporting III (2022)
Journal Article

Scientists who plan to publish in British Journal of Pharmacology (BJP) must read this article before undertaking a study. This editorial provides guidance for the design of experiments. We have published previously two guidance documents on experime... Read More about Planning experiments: Updated guidance on experimental design and analysis and their reporting III.

Community guidelines for GPCR ligand bias: IUPHAR review 32 (2022)
Journal Article

GPCRs modulate a plethora of physiological processes and mediate the effects of one-third of FDA-approved drugs. Depending on which ligand activates a receptor, it can engage different intracellular transducers. This ‘biased signalling’ paradigm requ... Read More about Community guidelines for GPCR ligand bias: IUPHAR review 32.

Editorial policy regarding the citation of preprints in the British Journal of Pharmacology (BJP) (2021)
Journal Article

Neuromolecular Mechanisms of Cannabis Action (2020)
Book Chapter

Most of our current understanding of the neuromolecular mechanisms of Cannabis action focusses on two plant cannabinoids, THC and CBD. THC acts primarily through presynaptic CB cannabinoid receptors to regulate neurotransmitter release in the brain,... Read More about Neuromolecular Mechanisms of Cannabis Action.

A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development. IUPHAR Review 29 (2020)
Journal Article

This article is protected by copyright. All rights reserved. In this review, we identify opportunities for drug discovery in the treatment of COVID-19 and in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate a... Read More about A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development. IUPHAR Review 29.

Hydrolases (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database (2019)
Journal Article

Cannabinoids and their actions: An update (2019)
Journal Article

Linked Articles: This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.

n−3 polyunsaturated N-acylethanolamines are CB2 cannabinoid receptor-preferring endocannabinoids (2018)
Journal Article

Anandamide, the first identified endogenous cannabinoid and TRPV1 agonist, is one of a series of endogenous N-acylethanolamines, NAEs. We have generated novel assays to quantify the levels of multiple NAEs in biological tissues and their rates of hyd... Read More about n−3 polyunsaturated N-acylethanolamines are CB2 cannabinoid receptor-preferring endocannabinoids.

Cannabinoid ligands, receptors and enzymes: pharmacological tools and therapeutic potential (2018)
Journal Article

Endocannabinoids have been identified to have roles in numerous physiological and pathological processes. Largely due to the association of the effects of Cannabis administration on mental states, the CNS impact of the endocannabinoid system has been... Read More about Cannabinoid ligands, receptors and enzymes: pharmacological tools and therapeutic potential.

Coronary artery hypoxic vasorelaxation is augmented by perivascular adipose tissue through a mechanism involving hydrogen sulfide and cystathionine-β-synthase (2018)
Journal Article

Aim: Hypoxia causes vasodilatation of coronary arteries which protects the heart from ischaemic damage through mechanisms including the generation of hydrogen sulfide (H2S), but the influence of the perivascular adipose tissue (PVAT) and myocardium i... Read More about Coronary artery hypoxic vasorelaxation is augmented by perivascular adipose tissue through a mechanism involving hydrogen sulfide and cystathionine-β-synthase.

Effects of the cannabinoid CB1 agonist ACEA on salicylate ototoxicity, hyperacusis and tinnitus in guinea pigs (2017)
Journal Article

Cannabinoids have been suggested as a therapeutic target for a variety of brain disorders. Despite the presence of their receptors throughout the auditory system, little is known about how cannabinoids affect auditory function. We sought to determine... Read More about Effects of the cannabinoid CB1 agonist ACEA on salicylate ototoxicity, hyperacusis and tinnitus in guinea pigs.

Preface (2017)
Journal Article

A critical role for cystathionine-?-synthase in hydrogen sulfide-mediated hypoxic relaxation of the coronary artery (2017)
Journal Article

Hypoxia-induced coronary artery vasodilatation protects the heart by increasing blood flow under ischemic conditions, however its mechanism is not fully elucidated. Hydrogen sulfide (H2S) is reported to be an oxygen sensor/transducer in the vasculatu... Read More about A critical role for cystathionine-?-synthase in hydrogen sulfide-mediated hypoxic relaxation of the coronary artery.